Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
capecitabine + oxaliplatin + PD-1 inhibitor
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Capecitabine + oxaliplatin + PD-1 inhibitor is a neoadjuvant chemoimmunotherapy regimen primarily investigated for the treatment of locally advanced rectal cancer. This combination, often referred to as CAPOX (or XELOX) plus a PD-1 inhibitor, integrates standard-of-care chemotherapy with immune checkpoint blockade. Capecitabine is an oral prodrug of 5-fluorouracil that inhibits thymidylate synthase, while oxaliplatin is a platinum agent that induces DNA crosslinking and immunogenic cell death. The addition of a PD-1 inhibitor, such as sintilimab, aims to overcome the immunosuppressive microenvironment of proficient mismatch repair (pMMR) or microsatellite stable (MSS) tumors by restoring T-cell mediated anti-tumor activity. This triplet regimen is frequently evaluated in conjunction with short-course radiotherapy (SCRT) to improve pathological complete response (pCR) rates.
- Other names
- CAPOX plus PD-1 inhibitorXELOX plus PD-1 inhibitor
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on capecitabine + oxaliplatin + PD-1 inhibitor.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on capecitabine + oxaliplatin + PD-1 inhibitor.